文献速递妇科肿瘤

子宫内膜癌分子分型时代的 surgical stage

Surgical stage in the era of molecular profiling of endometrial cancer.
PubMed 文献 · Eur J Cancer · 2025-12-05

这项多中心回顾性研究纳入1994至2018年间11个欧洲中心的2056例子宫内膜癌患者,覆盖所有组织学亚型与FIGO分期,按POLEmut、MMRd、NSMP和p53abn分为四个分子亚组。多变量分析显示癌症特异性生存独立关联分子亚型、FIGO分期、年龄、组织学类型、分级、淋巴血管间隙浸润、辅助治疗、残留肿瘤和淋巴结清扫;FIGO分期在各分子亚组内均与癌症特异性死亡显著相关(p < 0.001),提示手术分期在分子分型时代仍是强预后因素。

要点

  • FIGO分期在各分子亚组内均与癌症特异性死亡显著相关(p < 0.001)。
  • 肿瘤局限于子宫者预后最佳。
  • 淋巴结转移显著降低POLEmut、MMRd和p53abn组的癌症特异性生存。

核心结论

  • 手术分期在分子分型时代仍是子宫内膜癌的强预后因素,应与分子分类共同用于辅助治疗决策。

研究设计与样本

  • 多中心回顾性研究纳入11个欧洲中心1994至2018年治疗的2056例子宫内膜癌患者,覆盖所有组织学亚型和FIGO分期。

主要发现

  • FIGO I、II、III、IV期分别占69%、9%、16%、6%,分子亚组POLEmut、MMRd、NSMP、p53abn分别占8%、28%、44%、21%。
  • 总体5年癌症特异性死亡率为16.5%(95% CI 14.9%-18.2%),复发率为23.8%(95% CI 22.0%-25.7%)。
  • 多变量分析中癌症特异性生存独立关联分子亚型、FIGO分期、年龄、组织学类型、分级、淋巴血管间隙浸润、辅助治疗、残留肿瘤和淋巴结清扫。
  • FIGO分期在各分子亚组内均与癌症特异性死亡显著相关(p < 0.001)。
  • 淋巴结转移显著降低POLEmut、MMRd和p53abn组的癌症特异性生存,FIGO IV期内分子亚型与结局无显著相关。

临床怎么用

  • 在制定子宫内膜癌辅助治疗时,应同时考虑手术分期与分子分型,而非仅依赖分子分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Molecular classification has reshaped risk stratification in endometrial cancer (EC), yet the relevance of tumor spread within molecular subgroups has not been reported so far. MATERIAL AND METHODS: This multicenter retrospective study included 2056 EC patients treated between 1994 and 2018 across 11 European centers. All histopathological subtypes and FIGO stages were included. Tumors were classified into four molecular subgroups: POLE-mutated (POLEmut), mismatch repair deficient (MMRd), no specific molecular profile (NSMP), and TP53/p53 abnormal (p53abn). Clinical and pathological data were extracted from existing cohort databases. RESULTS: Patients were diagnosed with FIGO stage I (69 %), II (9 %), III (16 %), and IV (6 %), and classified into: POLEmut (8 %), MMRd (28 %), NSMP (44 %), and p53abn (21 %). The overall 5-year cancer-specific death (CSD) and recurrence rates were 16.5 % (95 % CI, 14.9 %-18.2 %) and 23.8 % (95 % CI, 22.0 %-25.7 %), respectively. In multivariable analysis cancer-specific survival (CSS) was independently associated with molecular subtype, FIGO stage, age, histopathological type, grade, lymphovascular space invasion, adjuvant therapy, residual tumor, and lymphadenectomy. FIGO stage was significantly associated with CSD also in within each molecular subgroup (p < 0.001). Patients with tumors confined to the uterus had the most favourable prognosis. Lymph node metastases significantly decreased CSS in POLEmut, MMRd, and p53abn groups. Within FIGO stage IV, molecular subtype was not significantly related to outcome. DISCUSSION: Surgical stage remains a strong prognostic factor across molecular subtypes and should be considered alongside molecular classification when tailoring adjuvant treatment in EC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kasius JC, Kildal W, Vrede SW, et al. Surgical stage in the era of molecular profiling of endometrial cancer. Eur J Cancer. 2025. PMID: 41385938. doi:10.1016/j.ejca.2025.116164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。